Health2Sync's innovative technology empowers patients with diabetes to take control of their health, and this public-private collaboration can further reduce the burden on healthcare systems.
Insulet (NASDAQ:PODD – Free Report) had its target price hoisted by JPMorgan Chase & Co. from $280.00 to $330.00 in a research report sent to investors on Thursday morning,Benzinga reports. They ...
The intelligent microgrid system, built in the Port of Lianyungang ... Meanwhile, the pilot ports are building smart energy management platforms to monitor energy consumption, record energy sources ...